JP2018109068A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018109068A5 JP2018109068A5 JP2018076529A JP2018076529A JP2018109068A5 JP 2018109068 A5 JP2018109068 A5 JP 2018109068A5 JP 2018076529 A JP2018076529 A JP 2018076529A JP 2018076529 A JP2018076529 A JP 2018076529A JP 2018109068 A5 JP2018109068 A5 JP 2018109068A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- halogen
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 40
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 239000012453 solvate Substances 0.000 claims 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 9
- 150000004677 hydrates Chemical class 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- 102000003964 Histone deacetylase Human genes 0.000 claims 4
- 108090000353 Histone deacetylase Proteins 0.000 claims 4
- -1 —C 3-12 cyclo Alkyl Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130154455 | 2013-12-12 | ||
| KR10-2013-0154455 | 2013-12-12 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016539198A Division JP2016540024A (ja) | 2013-12-12 | 2014-12-12 | 新規な選択的ヒストン脱アセチル化酵素阻害剤としてのアザインドール誘導体およびこれを含む薬剤学的組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018109068A JP2018109068A (ja) | 2018-07-12 |
| JP2018109068A5 true JP2018109068A5 (enExample) | 2018-10-11 |
| JP6561167B2 JP6561167B2 (ja) | 2019-08-14 |
Family
ID=53370682
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016539198A Pending JP2016540024A (ja) | 2013-12-12 | 2014-12-12 | 新規な選択的ヒストン脱アセチル化酵素阻害剤としてのアザインドール誘導体およびこれを含む薬剤学的組成物 |
| JP2018076529A Expired - Fee Related JP6561167B2 (ja) | 2013-12-12 | 2018-04-12 | 新規な選択的ヒストン脱アセチル化酵素阻害剤としてのアザインドール誘導体およびこれを含む薬剤学的組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016539198A Pending JP2016540024A (ja) | 2013-12-12 | 2014-12-12 | 新規な選択的ヒストン脱アセチル化酵素阻害剤としてのアザインドール誘導体およびこれを含む薬剤学的組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9650379B2 (enExample) |
| EP (1) | EP3080125B1 (enExample) |
| JP (2) | JP2016540024A (enExample) |
| KR (1) | KR101689394B1 (enExample) |
| CN (1) | CN105940001B (enExample) |
| DK (1) | DK3080125T3 (enExample) |
| ES (1) | ES2704704T3 (enExample) |
| HR (1) | HRP20181965T1 (enExample) |
| PL (1) | PL3080125T3 (enExample) |
| PT (1) | PT3080125T (enExample) |
| TR (1) | TR201900057T4 (enExample) |
| WO (1) | WO2015087151A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015157504A1 (en) | 2014-04-11 | 2015-10-15 | Taipei Medical University | Histone deacetylase inhibitors |
| PL3328843T3 (pl) | 2015-07-27 | 2023-02-27 | Chong Kun Dang Pharmaceutical Corp. | Związki będące pochodnymi 1,3,4 oksadiazolosulfonamidów jako inhibitor deacetylazy histonowej 6, oraz kompozycja farmaceutyczna je zawierająca |
| NZ739211A (en) | 2015-07-27 | 2019-05-31 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same |
| RU2695227C9 (ru) * | 2015-07-27 | 2020-03-04 | Чонг Кун Данг Фармасьютикал Корп. | Производные 1,3,4-оксадиазолсульфамида в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция |
| PT3331864T (pt) | 2015-08-04 | 2022-01-18 | Chong Kun Dang Pharmaceutical Corp | Compostos derivados de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica compreendendo os mesmos |
| CA3001666C (en) | 2015-10-12 | 2021-03-30 | Chong Kun Dang Pharmaceutical Corp. | Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| EP3429591B1 (en) | 2016-03-16 | 2023-03-15 | Kura Oncology, Inc. | Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use |
| KR102002581B1 (ko) * | 2016-10-04 | 2019-07-22 | 주식회사 종근당 | 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물 |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| IT201700041723A1 (it) | 2017-04-14 | 2018-10-14 | Italfarmaco Spa | Nuovi inibitori selettivi di HDAC6 |
| TW201920170A (zh) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
| KR102236356B1 (ko) | 2017-11-24 | 2021-04-05 | 주식회사 종근당 | 루푸스의 예방 또는 치료를 위한 조성물 |
| KR102316234B1 (ko) | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| US20220296599A1 (en) * | 2018-10-12 | 2022-09-22 | Chong Kun Dang Pharmaceutical Corp. | Pharmaceutical composition comprising histone deacetylase inhibitor and methotrexate |
| MY207444A (en) | 2019-05-31 | 2025-02-27 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| BR112021026334A2 (pt) | 2019-06-27 | 2022-05-10 | Medstar Health | Macrófagos ativados por hdac6, composições, e usos dos mesmos |
| WO2021021979A2 (en) | 2019-07-30 | 2021-02-04 | Eikonizo Therapapeutics, Inc. | Hdac6 inhibitors and uses thereof |
| UY38912A (es) * | 2019-10-09 | 2021-05-31 | Biocryst Pharm Inc | Inhibidores del factor d del complemento para administración oral |
| EP4504190A4 (en) | 2022-04-08 | 2026-03-25 | Eikonizo Therapeutics Inc | OXADIAZOLE HDAC6 INHIBITORS AND THEIR USES |
| CN115417877B (zh) * | 2022-09-20 | 2024-05-14 | 杭州师范大学 | 组蛋白去乙酰化酶抑制剂及其制备和在制备抗癌症药物上的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE38506E1 (en) | 1991-10-04 | 2004-04-20 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| JP4975941B2 (ja) | 2000-09-29 | 2012-07-11 | トポターゲット ユーケー リミテッド | （ｅ）−ｎ−ヒドロキシ−３−（３−スルファモイル−フェニル）アクリルアミド化合物及びその治療用途 |
| US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| BRPI0817897A2 (pt) * | 2007-11-02 | 2019-09-24 | Methylgene Inc | composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac |
| JP2011506335A (ja) * | 2007-12-06 | 2011-03-03 | シェーリング コーポレイション | γ−セクレターゼ調節剤 |
| KR101168801B1 (ko) | 2009-03-27 | 2012-07-25 | 주식회사종근당 | 신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물 |
| US8431538B2 (en) | 2009-07-22 | 2013-04-30 | The Board Of Trustees Of The University Of Illinois | HDAC inhibitors and therapeutic methods of using same |
| US9249087B2 (en) * | 2011-02-01 | 2016-02-02 | The Board Of Trustees Of The University Of Illinois | HDAC inhibitors and therapeutic methods using the same |
| CA2840380A1 (en) * | 2011-06-24 | 2012-12-27 | Dana-Farber Cancer Institute, Inc. | Selective inhibitors of histone deacetylase isoform 6 and methods thereof |
| CA2850757A1 (en) | 2011-10-03 | 2013-04-11 | The Trustees Of Columbia University In The City Of New York | Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1 |
| CA2846066A1 (en) * | 2011-10-28 | 2013-05-02 | Chong Kun Dang Pharmaceutical Corp. | Hydroxamate derivatives for hdac inhibitor, and the pharmaceutical composition comprising thereof |
| CN103974956B (zh) | 2011-11-29 | 2016-07-06 | 南京奥昭生物科技有限公司 | 作为hdac6抑制剂和用作抗肿瘤剂的杂环酰胺化合物 |
-
2014
- 2014-12-12 EP EP14869323.7A patent/EP3080125B1/en active Active
- 2014-12-12 PL PL14869323T patent/PL3080125T3/pl unknown
- 2014-12-12 PT PT14869323T patent/PT3080125T/pt unknown
- 2014-12-12 KR KR1020140179702A patent/KR101689394B1/ko not_active Expired - Fee Related
- 2014-12-12 WO PCT/IB2014/002768 patent/WO2015087151A1/en not_active Ceased
- 2014-12-12 DK DK14869323.7T patent/DK3080125T3/en active
- 2014-12-12 US US15/103,597 patent/US9650379B2/en not_active Expired - Fee Related
- 2014-12-12 ES ES14869323T patent/ES2704704T3/es active Active
- 2014-12-12 HR HRP20181965TT patent/HRP20181965T1/hr unknown
- 2014-12-12 CN CN201480073461.XA patent/CN105940001B/zh not_active Expired - Fee Related
- 2014-12-12 TR TR2019/00057T patent/TR201900057T4/tr unknown
- 2014-12-12 JP JP2016539198A patent/JP2016540024A/ja active Pending
-
2018
- 2018-04-12 JP JP2018076529A patent/JP6561167B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021516237A5 (enExample) | ||
| JP2018531218A5 (enExample) | ||
| JP2020500178A5 (enExample) | ||
| JP2005517675A5 (enExample) | ||
| EP4473980A3 (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers | |
| JP2019513770A5 (enExample) | ||
| JP2020519664A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| JP2014508753A5 (enExample) | ||
| JP2015524457A5 (enExample) | ||
| JP2017517538A5 (enExample) | ||
| JP2017509586A5 (enExample) | ||
| JP2017536395A5 (enExample) | ||
| JP2018135343A5 (enExample) | ||
| JP2007504171A5 (enExample) | ||
| JP2015523385A5 (enExample) | ||
| JP2008510828A5 (enExample) | ||
| JP2010527913A5 (enExample) | ||
| JP2010523476A5 (enExample) | ||
| JP2015143283A5 (enExample) | ||
| JP2012528839A5 (enExample) | ||
| JP2017525699A5 (enExample) | ||
| JP2015512883A5 (enExample) | ||
| JP2018500287A5 (enExample) | ||
| JP2021513547A5 (enExample) |